Mesuximide

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Mesuximide
Mesuximide.svg
Clinical data
Trade names Celontin
AHFS/Drugs.com Consumer Drug Information
MedlinePlus a682028
Pregnancy
category
  • US: C (Risk not ruled out)
Routes of
administration
By mouth (capsules)
ATC code
Legal status
Legal status
Pharmacokinetic data
Metabolism Hepatic (demethylation and glucuronidation)
Metabolites N-desmethylmethosuximide
Biological half-life 1.4–2.6 hours (mesuximide)
28–38 hours (active metabolite)
Excretion Urine
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
ECHA InfoCard 100.000.934
Chemical and physical data
Formula C12H13NO2
Molar mass 203.237 g/mol
3D model (Jmol)
Chirality Racemic mixture
 NYesY (what is this?)  (verify)

Mesuximide (or methsuximide, methosuximide) is a succinimide anticonvulsant medication. It is sold as a racemate by Pfizer under the tradenames Petinutin (Switzerland)[1] and Celontin (United States).[2] The therapeutic efficacy of methosuximide is largely due to its pharmacologically active metabolite, N-desmethylmethosuximide, which has a longer half-life and attains much higher plasma levels than its parent.[3]

Medical use[edit]

is indicated for the control of absence seizures that are refractory to other drugs.[2]

References[edit]

  1. ^ Pfizer AG (2005). "Petinutin (Mésuximide)". Official Pfizer AG Website (in French). Archived from the original on April 22, 2005. Retrieved August 21, 2006. 
  2. ^ a b Pfizer Inc. (2008). "Celontin (methsuximide capsules, USP)". Official Pfizer Inc. Website. Retrieved November 21, 2014. 
  3. ^ Porter RJ, Penry JK, Lacy JR, Newmark ME, Kupferberg HJ. Plasma concentrations of phensuximide, methosuximide, and their metabolites in relation to clinical efficacy. Neurology 29: 1509-1513, 1979.